In a groundbreaking advancement within pediatric oncology, researchers at the University of Birmingham have uncovered a novel biomarker that could revolutionize the prediction of treatment response in children suffering from Ewing Sarcoma and other challenging solid tumors. This discovery stems from a meticulously conducted Phase I/II clinical trial embedded in the broader AcSé-eSMART study, a multi-national effort orchestrated by the Cancer Research UK Clinical Trials Unit and international sponsor Gustave Roussy. The investigation specifically targeted the efficacy and safety of combining a well-known chemotherapy agent, irinotecan, with a PARP inhibitor, Olaparib—a DNA repair inhibitor previously validated in adult oncology.
The trial enrolled 70 pediatric and young adult participants diagnosed with recalcitrant or recurrent solid tumors, of which 66 underwent active treatment across four countries: the UK, France, the Netherlands, and Spain. This patient cohort was heterogeneous, incorporating 36 individuals with Ewing Sarcoma alongside 34 patients who had a diverse array of tumor types. Among these other malignancies were osteosarcoma—a primary bone cancer, neuroblastoma arising from the adrenal medulla or sympathetic nervous system, rhabdomyosarcoma from soft tissues resembling skeletal muscle, nephroblastoma, a pediatric renal tumor, and rare brain cancers such as medulloblastoma and choroid plexus carcinoma.
Historically, the prognosis for children with these aggressive tumors has been grim, especially in relapsed or metastatic cases, with cure rates dwindling below thirty percent. Most participants in this trial had undergone multiple prior treatments, underscoring the refractory nature of their disease and the urgent need for novel therapeutic strategies. The trial’s objective was twofold: to evaluate the tolerability and clinical efficacy of low-dose irinotecan combined with the PARP inhibitor Olaparib in a pediatric setting, and to discern whether certain tumor genetic profiles—particularly those involving defective DNA repair pathways—correlated with a better therapeutic response.
The rationale for using PARP inhibitors in this context is rooted in their mechanism of exploiting synthetic lethality in cancers with homologous recombination repair deficiencies. Ewing Sarcoma, in particular, has demonstrated in vitro vulnerabilities suggestive of impaired DNA repair machinery analogous to adult tumors responsive to PARP inhibitors. However, the clinical translation of this hypothesis remained unproven until this study. While the treatment achieved some degree of disease stabilization or tumor shrinkage in 12 patients, spanning multiple tumor types, the anticipated genomic indicators such as specific gene mutations involved in DNA repair pathways or even the histologic classification of Ewing Sarcoma did not reliably predict which patients would benefit.
A transformative insight came from a detailed retrospective genomic analysis that quantified aneuploidy levels within patients’ tumor cells. Aneuploidy, the presence of an abnormal number of chromosomes, emerged as a highly significant marker. Patients exhibiting a high aneuploidy score were substantially more likely to respond favorably to the combination therapy of Olaparib and irinotecan, independent of their tumor histology or known gene alterations. This correlation introduces an entirely new dimension to personalizing pediatric cancer treatment, as aneuploidy could function as a unifying biomarker to identify those tumors most susceptible to DNA repair inhibition.
Dr. Louise Hopkins, who leads the trial management team at the Cancer Research UK Clinical Trials Unit, emphasized the potential shift in clinical paradigms this discovery heralds. By enabling oncologists to stratify patients based on aneuploidy scores rather than solely on genetic mutations or tumor type, the approach promises to optimize therapeutic efficacy and minimize exposure to ineffective treatments. This individualized strategy represents a pioneering step in overcoming the notorious heterogeneity and unpredictability that characterize relapse in pediatric solid tumors.
The study also highlights the vital role of international collaboration in tackling complex cancers. The multi-center nature of this trial, spanning several European countries, allowed for a diverse patient population that enhanced the robustness and generalizability of the findings. Moreover, the integration of genomic technologies with clinical endpoints exemplifies the future of precision medicine—wherein comprehensive molecular profiling informs real-world treatment decisions.
While the data are promising, Dr. Susanne Gatz of the University of Birmingham’s Department of Cancer and Genomic Sciences urged cautious optimism, stressing the necessity for additional research. The aetiological and mechanistic underpinnings linking high aneuploidy with heightened susceptibility to PARP inhibition remain to be elucidated. Further studies will be essential to determine whether aneuploidy serves merely as a prognostic indicator or if it actively modulates the DNA damage response pathways targeted by these therapies.
Importantly, this research marks the first occasion in pediatric oncology trials where aneuploidy has been directly correlated with treatment response. The implications extend beyond the confines of pediatric cancers; should subsequent validation studies confirm its utility, aneuploidy scoring could become an invaluable biomarker across diverse tumor types and age groups, potentially transforming the landscape of DNA repair inhibitor clinical trials across oncology.
In addition to its scientific significance, the study also affirms the importance of patient and family participation in clinical research, particularly for rare and refractory conditions where conventional treatment options are scarce. The success of this trial is a testament to their commitment and hope, driving forward progress where it is most desperately needed.
This discovery underscores the accelerating convergence of genomic science, molecular targeted therapies, and clinical trial design to address unmet needs in cancer treatment. By illuminating the role of aneuploidy as a predictive biomarker, the study opens new avenues for optimizing therapeutic regimens, increasing the likelihood of clinical benefit, and ultimately improving survival outcomes for children afflicted with some of the most intractable malignancies known.
As research continues to unravel the intricate genomic landscapes that govern tumor behavior and drug responsiveness, this breakthrough from the University of Birmingham provides a luminous beacon, guiding the next generation of personalized pediatric cancer therapies.
Subject of Research: People
Article Title: Phase I/II Study of the PARP Inhibitor Olaparib and Irinotecan in Children and Young Adults with Recurrent/Refractory Malignancies: Arm D of the AcSé-ESMART Trial
News Publication Date: 1-Apr-2026
Web References:
http://dx.doi.org/10.1158/1078-0432.CCR-25-3767
Keywords:
Cancer research, Cancer treatments, Pediatric oncology, Ewing Sarcoma, PARP inhibitors, Olaparib, Irinotecan, Aneuploidy, DNA repair, Clinical trials, Precision medicine, Solid tumors
Tags: AcSé-eSMART study pediatric cancerschemotherapy resistance in pediatric solid tumorsEwing Sarcoma treatment responseirinotecan and Olaparib combination therapymulti-national pediatric cancer researchneuroblastoma treatment advancesosteosarcoma novel therapiesPARP inhibitors in childhood tumorspediatric cancer biomarkerspediatric sarcoma therapeutic strategiesPhase I/II pediatric oncology clinical trialrare pediatric brain cancer trials
